1.86
-0.04
(-2.11%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 1.86 - 1.93 |
| 52 week | 0.59 - 2.67 |
| Open | 1.92 |
| Vol / Avg. | 387,369.00/372,607.00 |
| Mkt cap | 72.31M |
| P/E | - |
| Div/yield | - |
| EPS | -1.03 |
| Shares | 38.88M |
| Beta | 0.42 |
| Inst. own | 7% |
Events
May 9, 2013
Q1 2013 StemCells, Inc. Earnings Conference Call -
Apr 17, 2013
StemCells, Inc. at 2013 Regen Med Investor Day -
Mar 21, 2013
Q4 and 2012 StemCells, Inc. Earnings Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -1306.77% | -2082.75% |
| Operating margin | -3218.02% | -1648.12% |
| EBITD margin | - | -1549.56% |
| Return on average assets | -36.99% | -102.90% |
| Return on average equity | -95.35% | -230.61% |
| Employees | 49 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 140, 7707 Gateway Blvd
NEWARK, CA 94560
United States - Map
+1-510-4564000 (Phone)
+1-510-4564001 (Fax)
NEWARK, CA 94560
United States - Map
+1-510-4564000 (Phone)
+1-510-4564001 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�s human liver cells as a therapeutic product.
Officers and directors
| John J. Schwartz Ph.D. | Independent Chairman of the Board | |
| Martin M. McGlynn | President, Chief Executive Officer, Director | |
| Rodney K. B. Young | Chief Financial Officer, Vice President - Finance and Administration | |
| Ann Tsukamoto Ph.D. | Executive Vice President - Research and Development | |
| Stewart Craig Ph.D. | Senior Vice President - Development and Operations | |
| Kenneth Stratton J.D. | General Counsel | |
| Irving L Weissman M.D. | Director | |
| Eric H Bjerkholt | Independent Director | |
| R. Scott Greer | Independent Director | |
| Ricardo B. Levy Ph.D. | Independent Director |